The Phase 3 GLORY-2 study of mazdutide 9 mg in Chinese adults with moderate to severe obesity was simultaneously published in JAMA and presented at the ADA Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 8 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of Phase 3 clinical study of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) are presented as an oral presentation (1225-OR) at the 2026 American Diabetes Association (ADA) Scientific Sessions, and simultaneously published online in the internationally renowned journal The Journal of the American Medical Association (JAMA). The first authors are Leili Gao from Peking University People’s Hospital and Prof. Hongwei Jiang from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Prof. Linong Ji from Peking University People’s Hospital and Dr. Lei Qian from Innovent Biologics are co-corresponding authors of this article. China faces a high prevalence of obesity. Individuals with a BMI exceeding 30 kg/m² often carry a heavier burden of cardiometabolic diseases, this population requires special attention in clinical weight management and in the prevention and treatment of metabolic syndrome. Currently, this population has unmet clinical needs in terms of pharmacotherapeutic treatment. The findings from the GLORY-2 clinical study may offer a new therapeutic alternative, addressing the unmet need for weight management in this population. GLORY-2 (NCT06164873) is a Phase 3 clinical study to evaluate the efficacy and safety of mazdutide 9 mg combined with lifestyle intervention versus placebo in Chinese adults with obesity (BMI ≥30 kg/m²). The study enrolled 462 participants (including 16% with type 2 diabetes), randomized in a 2:1 ratio to receive mazdutide 9 mg group or placebo in the 60-week double-blind treatment period (mean baseline weight: 94.0 kg; mean BMI: 34.3 kg/m²). The mean baseline weight of enrolled participants was 94.0 kg; mean BMI was 34.3 kg/m². During the treatment period, participants in the mazdutide 9 mg group exhibited continuous weight loss, with no plateau observed in Week 60. At Week 60, the mazdutide 9 mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide 9 mg group achieved a weight reduction of 20% or more, versus 2.6% in the placebo group (P<0.0001 for all comparisons). In this study of participants with obesity and without Type 2 diabetes, the mazdutide 9 mg group showed a mean weight reduction of 20.08% at Week 60 (placebo: 2.81%), with 48.7% of participants achieving a weight reduction of 20% or more (placebo: 3.1%; P<0.0001). Furthermore, mazdutide was superior to placebo in comparisons of changes in secondary endpoints including, other body weight endpoints, waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and serum uric acid levels. This study also evaluated changes in liver fat content using MRI-PDFF in a subset of participants. In this study of participants with obesity and without Type 2 diabetes whose baseline liver fat content ≥10%, the mean percent change in liver fat content from baseline to week 60 was -71.9% in the mazdutide 9 mg group compared with 5.1% in the placebo group. Mazdutide 9 mg demonstrated favorable tolerability and safety profiles, with no new safety signals identified. The majority of gastrointestinal adverse events were mild to moderate in severity and transient in nature. The proportion of participants who discontinued treatment prematurely due to adverse events was 2.9% in the mazdutide 9 mg group and 0% in the placebo group. Professor Linong Ji, the leading principal investigator of the study, Peking University People’s Hospital, stated, "China has a high prevalence of obesity, and people with obesity carry a heavy burden of cardiometabolic diseases. Those with moderate‑to‑severe obesity merits close attention in clinical weight management and in the prevention and treatment of metabolic syndrome. The randomized, double-blinded and placebo-controlled GLORY‑2 study confirms the efficacy and safety of mazdutide 9 mg. As the principal investigator of the GLORY‑2 study, I am delighted that the results were simultaneously presented at the ADA Scientific Sessions and published in JAMA, earning high recognition from the international academic community, providing Chinese evidence for the treatment of obesity and metabolic diseases. We look forward to the mazdutide 9 mg will bring a safe, effective, and accessible new weight management option for Chinese adults with moderate-to-severe obesity and help improve metabolic health. We look forward to the timely approval and launch of mazdutide 9 mg, which will bring a safe, potent, and accessible stepped weight management strategy for people with obesity in China and help improve the metabolic health of the general population." Dr. Lei Qian, Chief R&D Officer (General Biomedicine), Innovent, stated, " It is a great honor to see the GLORY‑2 study results of mazdutide presented simultaneously at the ADA Scientific Sessions and published in JAMA. This represents both high recognition by the international academic community of China‑developed GCG/GLP‑1 dual receptor agonists, and a major milestone for Innovent Biologics in its deep commitment to the metabolic disease area and focus on the unmet needs of Chinese patients with moderate‑to‑severe obesity. The clinical results of mazdutide published in leading journals including Nature, The New England Journal of Medicine, Nature Communications, Diabetes Care, eClinicalMedicine, and Med (a Cell journal), setting multiple landmark records for innovative metabolic drugs developed in China. The renewed recognition of the GLORY‑2 study by prestigious international platforms fully validates mazdutide’s high‑quality, reproducible clinical benefits. It also signifies that China has joined the global first tier in metabolic drug R&D, providing solid Chinese evidence and Chinese solutions for the treatment of obesity and metabolic diseases. Mazdutide 9 mg is currently the only GLP‑1 agent that, with a 3‑step dose titration, achieves >20% weight loss after one year of treatment in obese individuals without type 2 diabetes, with weight continuing to decline without reaching a plateau. This clearly demonstrates the unique advantages of the dual‑target synergistic mechanism. Its development provides evidence‑based support for effective weight management beyond bariatric surgery for Chinese patients with moderate‑to‑severe obesity. The New Drug Application (NDA) for mazdutide 9 mg for weight management in adults was formally submitted in November 2025 and accepted by the National Medical Products Administration (NMPA). We look forward to its early approval and launch, which will deliver diverse solutions for different obesity phenotypes, support stepped weight management, and enable precision therapy. Furthermore, mazdutide’s life cycle management plan for patients continues to expand its boundaries. Based on scientific evidence and unmet medical needs, we will further advance the development of additional indications for mazdutide. Innovent Biologics will continue to build a next‑generation product pipeline in cardiovascular and metabolic diseases, striving to meet people’s aspirations for a better quality of life, serve more patients, and contribute to the Healthy China 2030 strategy." About Mazdutide Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists, such as promoting insulin secretion, lowering blood glucose and reducing body weight. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Mazdutide has been conducted in or completed a total of nine Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial (Mazdutide 4 mg and 6 mg) in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial (Mazdutide 9 mg) in Chinese participants with moderate-to-severe obesity. DREAMS-1: A Phase 3 trial in treatment-naïve Chinese participants with T2D. DREAMS-2: A Phase 3 trial comparing Mazdutide and dulaglutide in Chinese T2D participants with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing Mazdutide and semaglutide in Chinese participants with T2D and obesity. GLORY-3: A Phase 3 trial comparing Mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). GLORY-OSA: A Phase 3 trial in Chinese participants with OSA and obesity. GLORY-YOUNG: A Phase 3 trial in Chinese adolescents with obesity. GLORY-H: A Phase 3 trial in Chinese participants with obesity and hypertension. Among these, the first five Phase 3 studies have met primary endpoints, and the latter four Phase 3 trials remain ongoing. In addition, several clinical studies of mazdutide are ongoing, including studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF) and a head-to-head comparation of high-dose mazdutide versus tirzepatide for the treatment of moderate-to-severe obesity. *Mazdutide has received NMPA approval for two indications: Long-term weight control in adult patients As an adjunct to dietary control and increased physical activity in adults with initial BMI: ≥28 kg/m² (obesity), or ≥24 kg/m² (overweight) plus ≥1 weight-related comorbidity (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver disease, obstructive sleep apnea syndrome). Glycemic control in adults with T2D: Monotherapy: Adults with inadequately controlled T2D after diet/exercise intervention alone. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 1 asset under NMPA review, 4 assets in phase 3 or pivotal clinical trials, and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retsevmo®) and Pirtobrutinib Tablets (Jaypirca®) are products discovered and developed by Eli Lilly. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

The release as fetched from its publisher. innoventbio.com ↗